OTHERS CONTRACT FOR THE SUPPLY BY (1) DUOPHARMA (M) SENDIRIAN BERHAD; AND (2) DUOPHARMA MANUFACTURING (BANGI) SDN. BHD., (BOTH WHOLLY-OWNED SUBSIDIARY COMPANIES OF DUOPHARMA BIOTECH BERHAD), THROUGH PHARMANIAGA LOGISTICS SDN BHD, OF PHARMACEUTICAL AND/OR NON-PHARMACEUTICAL PRODUCTS FOR THE MINISTRY OF HEALTH OF MALAYSIA UNDER THE APPROVED PRODUCTS PURCHASE LIST (Announcement pursuant to Chapter 9 of Bursa Malaysia Securities Berhad Main Market Listing Requirements)
| DUOPHARMA BIOTECH BERHAD |
| Type | Announcement |
| Subject | OTHERS |
| Description | CONTRACT FOR THE SUPPLY BY (1) DUOPHARMA (M) SENDIRIAN BERHAD; AND (2) DUOPHARMA MANUFACTURING (BANGI) SDN. BHD., (BOTH WHOLLY-OWNED SUBSIDIARY COMPANIES OF DUOPHARMA BIOTECH BERHAD), THROUGH PHARMANIAGA LOGISTICS SDN BHD, OF PHARMACEUTICAL AND/OR NON-PHARMACEUTICAL PRODUCTS FOR THE MINISTRY OF HEALTH OF MALAYSIA UNDER THE APPROVED PRODUCTS PURCHASE LIST (Announcement pursuant to Chapter 9 of Bursa Malaysia Securities Berhad Main Market Listing Requirements) |
|
We refer to the announcement made by Duopharma Biotech Berhad (hereinafter referred to as the “Company” or “Duopharma Biotech”) on 30 April 2024 in relation to the contracts for the supply by Duopharma (M) Sendirian Berhad (“DMSB”) and Duopharma Manufacturing (Bangi) Sdn. Bhd. (“DMfgB”) (both wholly-owned subsidiary companies of Duopharma Biotech), through Pharmaniaga Logistics Sdn. Bhd. (hereinafter referred to as the “Customer”), of pharmaceutical and/or non-pharmaceutical products for the Ministry of Health Malaysia under the Approved Products Purchase List (“Announcement No. 1”). For consistency purposes, the abbreviations used in this announcement are the same as those previously defined in the Announcement unless otherwise defined herein.
Duopharma Biotech wishes to announce that as at to date – 1. DMSB has received and accepted an additional four (4) Letters of Offer (“LOO”); and 2. DMfgB has received and accepted an additional one (1) LOO, from the Customer for the supply of Products to the offices and facilities operated and controlled by the Government of Malaysia through the Customer (hereinafter referred to as the “Additional Contract(s)”). All the Additional Contract(s) shall remain valid and binding until 31 December 2026 or such other date as directed by the Government of Malaysia.
The total number of Products in aggregate to be supplied under all the Additional Contract(s) is 10 and the total estimated value in aggregate of all the Additional Contract(s) is approximately RM87,663,323.60 for the duration of the Additional Contract(s).
The total number of Products in aggregate to be supplied under all the Contract(s) referred to in the Announcement No. 1 plus the Additional Contract(s) is 96 and the total estimated value in aggregate of all the Contract(s) referred to in Announcement No. 1 plus the Additional Contract(s) is approximately RM665,756,799.32 for the duration of the Contract(s) referred to in the Announcement No. 1 and the Additional Contract(s) (i.e. until 31 December 2026 or such other date as directed by the Government of Malaysia).
The acceptance of the Additional Contract(s) from the Customer for the supply of the Products is in the ordinary course of business of the Company.
This announcement is dated 30 October 2024. |
|
Announcement Info
| Company Name | DUOPHARMA BIOTECH BERHAD |
| Stock Name | DPHARMA |
| Date Announced | 30 Oct 2024 |
| Category | General Announcement for PLC |
| Reference Number | GA1-30102024-00024 |